CD44 and gastric cancer: Most of these results were confirmed by multiple experimental replicates in the same cell line (two more replicates for CD44 KD and FGFR2 KD, respectively) (Figure S5A, S5B) and in a patient-derived primary GC cell line (Figure S5C) using three different shRNAs targeted to FGFR2 in the same SNU-16 cell line (Figure S5D).